Stock Analysis

NGL Fine-Chem Full Year 2024 Earnings: EPS: ₹66.88 (vs ₹33.18 in FY 2023)

Advertisement

NGL Fine-Chem (NSE:NGLFINE) Full Year 2024 Results

Key Financial Results

  • Revenue: ₹3.39b (up 22% from FY 2023).
  • Net income: ₹413.2m (up 102% from FY 2023).
  • Profit margin: 12% (up from 7.4% in FY 2023). The increase in margin was driven by higher revenue.
  • EPS: ₹66.88 (up from ₹33.18 in FY 2023).

NGLFINE Post-Clinical Trial Products

  • Launched (during full year): 6.
revenue-and-expenses-breakdown
NSEI:NGLFINE Revenue and Expenses Breakdown August 7th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

The primary driver behind last 12 months revenue was the Asia Pacific segment contributing a total revenue of ₹980.0m (29% of total revenue). Explore how NGLFINE's revenue and expenses shape its earnings.

NGL Fine-Chem shares are down 4.5% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 1 warning sign for NGL Fine-Chem that you should be aware of.

Valuation is complex, but we're here to simplify it.

Discover if NGL Fine-Chem might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About NSEI:NGLFINE

NGL Fine-Chem

Manufactures and sells pharmaceuticals and intermediates for usage in veterinary and human health in India, Europe, the Asia Pacific, the United States, and internationally.

Excellent balance sheet with slight risk.

Advertisement

Updated Narratives

CE
CEG logo
cementafriend on Constellation Energy ·

Constellation Energy Dividends and Growth

Fair Value:US$348.054.7% overvalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
KH
CRWV logo
Khagani on CoreWeave ·

CoreWeave's Revenue Expected to Rocket 77.88% in 5-Year Forecast

Fair Value:US$11033.5% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
PO
BIS logo
PortfolioPlus on Bisalloy Steel Group ·

Bisalloy Steel Group will shine with a projected profit margin increase of 12.8%

Fair Value:AU$6.7118.0% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

TH
TheWallstreetKing
MVIS logo
TheWallstreetKing on MicroVision ·

MicroVision will explode future revenue by 380.37% with a vision towards success

Fair Value:US$6098.4% undervalued
101 users have followed this narrative
10 users have commented on this narrative
20 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$250.3929.3% undervalued
936 users have followed this narrative
6 users have commented on this narrative
23 users have liked this narrative
OS
oscargarcia
GOOGL logo
oscargarcia on Alphabet ·

The company that turned a verb into a global necessity and basically runs the modern internet, digital ads, smartphones, maps, and AI.

Fair Value:US$3405.8% undervalued
140 users have followed this narrative
6 users have commented on this narrative
18 users have liked this narrative